血清ykl-40在宫颈癌诊断分期及疗效判断中的临床价值
摘要
目的探讨血清ykl-40在宫颈癌中的临床价值。方法采用酶联免疫吸附试验检测53例宫颈癌、35例宫颈上皮内瘤变患者及35名健康妇女的血清ykl-40的水平。结果宫颈癌组、宫颈上皮内瘤变组及健康妇女组(对照组)血清中ykl-40浓度的中位数分别为194.37、69.51和74.51 ng/m L。ykl-40浓度比较,宫颈癌组与其他两组之间差异均有统计学意义(P<0.01);正常对照组与宫颈上皮内瘤变组差异无统计学意义(P>0.05)。III/IV期宫颈癌患者血清ykl-40浓度高于I/II期患者(P<0.01)。44例I/II期宫颈癌术前血清ykl-40浓度的中位数178.25 ng/m L与术后163.92 ng/m L比较,差异有统计学意义(P<0.05)。结论血清ykl-40在宫颈癌的诊断、临床分期及手术治疗疗效判断方面均有一定的临床价值。
出处
《浙江预防医学》
2015年第1期93-95,共3页
Zhejiang Journal of Preventive Medicine
基金
温州市科技计划项目(Y20130124)
参考文献9
-
1Johansen JS, Bojesen SE, Price PA, et al. Plasma YKL -40 and total and disease - specific mortality in the general population [J]. ClinChem, 2010, 56 (10): 1580-1591.
-
2王秀玲,卢美松.YKL-40在妇科肿瘤中的研究新进展[J].医学综述,2012,18(13):2025-2027. 被引量:5
-
3Corradi M, Goldoni M, Alinovi R, et al. YKL- 40 and Mesothelin in the Blood of Patients with Malignant MesotheliomaLung Cancer and Asbestosis [ J ]. Anticancer research, 2013, 33 (12) : 5517 -5524.
-
4Wang D, Zhai B, Hu F, et al. High YKL- 40 Serum Concentration Is Correlated with Prognosis of Chinese Patients with Breast Cancer [J]. PloS one, 2012, 7 (12) : e51127.
-
5Itik V, Kemik O, Kemik A, et al. Serum YKL- 40 Levels in Patients with Gastric Cancer [J]. Biomark Cancer , 2011 (3) : 25 - 30.
-
6Zou L, He X, Zhang JW, et al. The efficacy of YKL -40 and CA125 as biomarker for epithelial ovarian cancer [ J]. Braz J Med Biol Res, 2010, 43 (12) : 1232 -1238.
-
7Peng C, Peng J, Jiang L, et al. YKL -40 protein levels and clinical outcome of human endometrial cancer [ J ]. J Int Med Res, 2010, 38 (4): 1448-1457.
-
8Johansen JS, Roslind A, Pallc C, et al. Serum YKL - 40 levels in patient with cervical cancer are elevated compared to patients with cervical intraepithelial neoplasia and healthy control [ C ]. ASCO Annal Meeting, 2006: 267.
-
9Mitsuhashi A, Matsui H, Usui H, et al. Serum YKL -40 as a marker for cervical adenocarcinoma [ J ]. Ann Oncol, 2009, 20 (1): 71 -77.
二级参考文献27
-
1Johansen ,IS, Williamson MK, Rice JS, et al. Identification of pro- teins secreted by human osteoblastic cells in culture [J]. J Bone Miner Res, 1992,7 (5) :501-512.
-
2Hakala BE, White C, Recklies AD. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovisl cells, is a mammalian member of a chitinase protein family [ J ]. Bid Chem, 1993,268 (34) :25803-25810.
-
3Johansen JS, Larsen LA, Price PA, et al. YKL-40 Protein expres- sion in the early developing human musculoskeletal system [ J ]. Histochem Cytochem ,2007,55 ( 12 ) : 1213-1228.
-
4Johansen JS, Schultz NA, Jensen BV, et al. Plasma YKL-40 : a po- tential new cancer biomarker? [ J ]. Future Oncol, 2009,5 ( 7 ) : 1065-1082.
-
5Bojesen SE,Johansen JS, Nordestgaard BG. Plasma YKL-40 levels in healthy subjects from the general population[ J]. Clin Chim Ac- ta,2011,412(9/10)709-712.
-
6Johansen JS, Pedersen AN, Schroll M, et al. High serum YKL-40 level in a cohort of octogenarians is associated with increased risk of all-cause mortality [ J ]. Clin Exp Immunol, 2008,151 ( 12 ) : 260 - 266.
-
7Ringsholt M, HogdM1 EV, Johansen JS, et al. YKL-40 protein ex- pression in normal adult human tissues an immunohistochemical study[ J]. J Mol Hist ,2007,38 ( 1 ) :33-43.
-
8Nutt CL,Betensky RA,Brewer MA,et al. YKL-40 is a differ-renti- ated diagnostic marker for histologic subtypes of high-gracle gliomas [J]. Clin Cancer Res,2005,11 (6) :2258-2264.
-
9Kolson DL. YKL-40 : a candidate biomarker for simian immunodefi- cienly virus and human immunodeficienly virus encephalitis? [J].Am J Patho1,2008,173 (1) :25-29.
-
10Ling H, Recklies AD. The chitinase 3-like protein human cartilage 39 ( HC-39 ) inhibits celluar responses to the inflammatory cytokines interleukin-1 and tumor necrosis factor alpha [ J ]. Bio Chem,2004, 380(Pt 3) :651-659.
共引文献4
-
1王剑.子宫内膜癌患者血清人附睾蛋白4、人软骨糖蛋白-39水平的变化及其临床意义[J].中国基层医药,2013,20(24):3753-3754. 被引量:3
-
2董晓霞,黄凌霄,吕杰强,方深慧,林晓华.血清YKL-40和SCCag联合检测在宫颈癌中的应用价值[J].温州医学院学报,2015,45(3):205-208. 被引量:3
-
3董晓霞,黄凌霄,陈育梅,陈晶晶,杨洁.检测血清甲壳质酶蛋白40和C-反应蛋白在子宫内膜异位症诊疗中的临床价值[J].中国卫生检验杂志,2016,26(13):1883-1885. 被引量:1
-
4辛礼辉,惠京.绒癌和胎盘部位滋养细胞肿瘤中YKL-40、HCG、HPL的表达及意义[J].临床与实验病理学杂志,2019,35(3):320-322. 被引量:6
-
1原晓勇,吴斌.血清TSGF在乳腺癌中的研究现状[J].现代临床医学,2011,37(2):83-84. 被引量:3
-
2杨焕莲,宋丽华.肿瘤标志物对肺癌疗效判断的临床价值[J].山东医药,2009,49(52):110-111. 被引量:5
-
3方立萍,吴紫权,宋晨,赵金波,张阳.CEA、CYFRA21-1和NSE在肺癌化疗疗效评估中的价值[J].肿瘤学杂志,2010,16(12):981-982. 被引量:5
-
4马忠泰,栗怀广,施学东.骨肉瘤的化疗与疗效判断[J].中华骨科杂志,2000,20(B12):44-46. 被引量:22
-
5贾文波,周重新,金同法.55例鼻咽癌内镜与CT检查诊断分期的比较[J].浙江肿瘤,1996,2(2):85-85.
-
6林其声,施雄文,徐书楷,蒋新宇.新辅助化疗对乳腺癌ki67、cox-2、p53表达的影响及其临床意义[J].中国当代医药,2009,16(24):13-14. 被引量:18
-
7吴一龙,廖美琳,蒋国樑,周清华,张明和,张熙增,汪蕙,王思愚,谷力加.局部晚期非小细胞肺癌诊断治疗之共识[J].中华肿瘤杂志,2002,24(6):576-578. 被引量:101
-
8严丽华.卡培他滨联合奥沙利铂与替吉奥联合奥沙利铂治疗进展期胃癌的对比研究[J].中国现代药物应用,2015,9(3):99-100. 被引量:7
-
9吴英杰,李影.基质金属蛋白酶-9在宫颈癌血清中表达及临床意义[J].黑龙江医药科学,2015,38(6):107-108. 被引量:3
-
10张永杰,彭素蓉,张彤.Ⅰ-Ⅱ期宫颈癌组织中CD44V6,MMP-2与VEGF-C蛋白的表达与预后的关系[J].实用癌症杂志,2005,20(4):371-373.